• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Oncomine 融合转录试剂盒在福尔马林固定、石蜡包埋肺癌标本中的性能。

Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.

机构信息

Department of Genome Biology, Kindai University Faculty of Medicine, Osaka, Japan.

Department of Surgery, Tokyo Medical University, Tokyo, Japan.

出版信息

Cancer Sci. 2019 Jun;110(6):2044-2049. doi: 10.1111/cas.14016. Epub 2019 May 3.

DOI:10.1111/cas.14016
PMID:30972901
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6549924/
Abstract

Gene fusions play an important role in the carcinogenesis of lung adenocarcinoma. The recent association of four oncogenic driver genes, ALK, ROS1, RET, and NTRK1, as lung tumor predictive biomarkers has increased the need for precision medicine. We used formalin-fixed, paraffin-embedded tissue samples of non-small cell lung cancer from 150 EGFR mutation-negative cases and 10 fusion status-known cases and compared the performance of the Oncomine Dx Fusion Transcript Test (ODxFT) with FISH break-apart for the detection of ALK, RET, and ROS1 fusion genes. RNA was extracted from the paraffin-embedded tissue samples with or without macrodissection under hematoxylin and eosin staining, and the ALK fusion gene was independently determined using these assays. Fusion detection analyses were successfully carried out using ODxFT in 150 cases, with only one invalid case. ALK fusion genes were detected at a frequency of 7.3% (11/150) in the lung cancer specimens. Concordance rate between the ODxFT and ALK-FISH analyses was 99.3% (148/149). Sensitivity and specificity were 91.7% and 99.3%, respectively. All the samples with a known fusion status were accurately matched between the two assays. Our results show a high concordance rate between the ODxFT and ALK-FISH analyses. ODxFT was thus validated as an effective method for detecting clinically significant ALK fusion genes in paraffin-embedded tissue samples.

摘要

基因融合在肺腺癌的致癌作用中发挥着重要作用。最近,ALK、ROS1、RET 和 NTRK1 这四个致癌驱动基因作为肺肿瘤预测生物标志物的关联,增加了对精准医疗的需求。我们使用了 150 例 EGFR 突变阴性病例和 10 例融合状态已知病例的福尔马林固定、石蜡包埋的非小细胞肺癌组织样本,并比较了 Oncomine Dx Fusion Transcript Test (ODxFT) 与 FISH 分离法检测 ALK、RET 和 ROS1 融合基因的性能。从有或无苏木精和伊红染色的大体解剖的石蜡包埋组织样本中提取 RNA,并使用这些检测方法独立确定 ALK 融合基因。ODxFT 成功地对 150 例病例进行了融合检测分析,仅有 1 例无效。在肺癌标本中,ALK 融合基因的检出率为 7.3%(11/150)。ODxFT 与 ALK-FISH 分析的一致性率为 99.3%(148/149)。灵敏度和特异性分别为 91.7%和 99.3%。两种检测方法在所有已知融合状态的样本中均能准确匹配。我们的结果表明,ODxFT 与 ALK-FISH 分析之间具有很高的一致性。因此,ODxFT 被验证为一种在石蜡包埋组织样本中检测临床显著的 ALK 融合基因的有效方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab0/6549924/777cb03ab5d8/CAS-110-2044-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab0/6549924/777cb03ab5d8/CAS-110-2044-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dab0/6549924/777cb03ab5d8/CAS-110-2044-g001.jpg

相似文献

1
Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.Oncomine 融合转录试剂盒在福尔马林固定、石蜡包埋肺癌标本中的性能。
Cancer Sci. 2019 Jun;110(6):2044-2049. doi: 10.1111/cas.14016. Epub 2019 May 3.
2
Identification of , , and Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.通过多重 mRNA 检测方法在晚期非小细胞肺癌福尔马林固定石蜡包埋样本中鉴定 、 和 融合。
Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.
3
Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer.ALK/ROS1双分裂荧光原位杂交探针在非小细胞肺癌中的验证
Lung Cancer. 2017 Sep;111:79-83. doi: 10.1016/j.lungcan.2017.07.016. Epub 2017 Jul 12.
4
Multiplex fluorescence in situ hybridization testing for anaplastic lymphoma kinase and c-ros oncogene 1 gene rearrangements on cytology smears in lung adenocarcinomas: comparative study with formalin-fixed paraffin-embedded sections.肺腺癌细胞学涂片上间变性淋巴瘤激酶和c-ros原癌基因1基因重排的多重荧光原位杂交检测:与福尔马林固定石蜡包埋切片的比较研究
J Am Soc Cytopathol. 2022 May-Jun;11(3):154-164. doi: 10.1016/j.jasc.2022.01.001. Epub 2022 Jan 13.
5
Multicenter evaluation of an automated, multiplex, RNA-based molecular assay for detection of ALK, ROS1, RET fusions and MET exon 14 skipping in NSCLC.多中心评估一种自动化、多重、基于 RNA 的分子检测方法,用于检测 NSCLC 中的 ALK、ROS1、RET 融合和 MET 外显子 14 跳跃。
Virchows Arch. 2024 Apr;484(4):677-686. doi: 10.1007/s00428-024-03778-9. Epub 2024 Mar 16.
6
Cytology specimens offer an effective alternative to formalin-fixed tissue as demonstrated by novel automated detection for ALK break-apart FISH testing and immunohistochemistry in lung adenocarcinoma.细胞学标本为福尔马林固定组织提供了一种有效的替代方法,新型自动化检测在肺腺癌的ALK断裂FISH检测和免疫组化中已证明了这一点。
Cancer Cytopathol. 2014 Nov;122(11):810-21. doi: 10.1002/cncy.21467. Epub 2014 Aug 5.
7
Expression of C-terminal ALK, RET, or ROS1 in lung cancer cells with or without fusion.在有或没有融合的肺癌细胞中表达 C 端 ALK、RET 或 ROS1。
BMC Cancer. 2019 Apr 3;19(1):301. doi: 10.1186/s12885-019-5527-2.
8
Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.多色荧光原位杂交检测肺癌细胞学样本中间变性淋巴瘤激酶和 ROS 原癌基因 1 受体酪氨酸激酶重排。
J Clin Pathol. 2020 Feb;73(2):96-101. doi: 10.1136/jclinpath-2019-206152. Epub 2019 Sep 27.
9
[A standardized protocol for detection of ALK protein expression and gene fusion in lung adenocarcinoma cytologic specimens].[一种用于检测肺腺癌细胞学标本中ALK蛋白表达及基因融合的标准化方案]
Zhonghua Zhong Liu Za Zhi. 2015 Oct;37(10):742-8.
10
A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens.一种基于TaqMan的灵敏且高通量的逆转录定量聚合酶链反应检测方法,能够有效地区分肺癌福尔马林固定石蜡包埋(FFPE)标本中的ALK重排与过表达。
Lung Cancer. 2016 Apr;94:114-20. doi: 10.1016/j.lungcan.2016.02.004. Epub 2016 Feb 10.

引用本文的文献

1
Targeted Sequencing Approach and Its Clinical Applications for the Molecular Diagnosis of Human Diseases.靶向测序方法及其在人类疾病分子诊断中的临床应用。
Cells. 2023 Feb 2;12(3):493. doi: 10.3390/cells12030493.
2
Detection of gene fusions using next-generation sequencing for patients with malignancy in China.在中国,使用下一代测序技术对恶性肿瘤患者进行基因融合检测。
Front Cell Dev Biol. 2022 Dec 15;10:1035033. doi: 10.3389/fcell.2022.1035033. eCollection 2022.
3
Clinical Utility and Performance of an Ultrarapid Multiplex RNA-Based Assay for Detection of ALK, ROS1, RET, and NTRK1/2/3 Rearrangements and MET Exon 14 Skipping Alterations.

本文引用的文献

1
Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.采用下一代测序方法检测肺癌患者中的已知和新型 ALK 融合转录本。
Sci Rep. 2017 Oct 2;7(1):12510. doi: 10.1038/s41598-017-12679-8.
2
ROS1 fusions in cancer: a review.癌症中的ROS1融合:综述
Future Oncol. 2016 Aug;12(16):1911-28. doi: 10.2217/fon-2016-0050. Epub 2016 Jun 3.
3
Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
一种超快速多重 RNA 检测分析用于 ALK、ROS1、RET、NTRK1/2/3 重排和 MET 外显子 14 跳跃改变的临床实用性和性能。
J Mol Diagn. 2022 Jun;24(6):642-654. doi: 10.1016/j.jmoldx.2022.03.006. Epub 2022 Apr 14.
4
Integrated analysis of long non-coding RNAs and mRNAs associated with malignant transformation of gastrointestinal stromal tumors.长链非编码 RNA 和 mRNA 与胃肠道间质瘤恶性转化相关的综合分析。
Cell Death Dis. 2021 Jul 3;12(7):669. doi: 10.1038/s41419-021-03942-y.
5
Application of Next Generation Sequencing in Laboratory Medicine.下一代测序在医学实验室中的应用。
Ann Lab Med. 2021 Jan;41(1):25-43. doi: 10.3343/alm.2021.41.1.25. Epub 2020 Aug 25.
6
Elevated mRNA Expression Levels of NCAPG are Associated with Poor Prognosis in Ovarian Cancer.NCAPG的mRNA表达水平升高与卵巢癌预后不良相关。
Cancer Manag Res. 2020 Jul 14;12:5773-5786. doi: 10.2147/CMAR.S253349. eCollection 2020.
7
Next Generation Sequencing for Gene Fusion Analysis in Lung Cancer: A Literature Review.肺癌基因融合分析的下一代测序:文献综述
Diagnostics (Basel). 2020 Jul 27;10(8):521. doi: 10.3390/diagnostics10080521.
综合基因组分析鉴定出一组荧光原位杂交未检测到的对克唑替尼敏感的ALK重排非小细胞肺癌。
Oncologist. 2016 Jun;21(6):762-70. doi: 10.1634/theoncologist.2015-0497. Epub 2016 May 31.
4
High prevalence of ALK+/ROS1+ cases in pulmonary adenocarcinoma of adoloscents and young adults.青少年和年轻成人肺腺癌中ALK+/ROS1+病例的高患病率。
Lung Cancer. 2016 Jul;97:95-8. doi: 10.1016/j.lungcan.2016.04.022. Epub 2016 May 2.
5
High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.肺癌中临床可操作基因融合的高通量诊断分析
Genes Chromosomes Cancer. 2016 Jan;55(1):30-44. doi: 10.1002/gcc.22297. Epub 2015 Sep 23.
6
Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience.肺腺癌多机构致癌驱动基因突变分析:肺癌突变联盟的经验
J Thorac Oncol. 2015 May;10(5):768-777. doi: 10.1097/JTO.0000000000000516.
7
The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.间变性淋巴瘤激酶(ALK)阳性非小细胞肺癌分子检测的外部质量评估的相关性:两轮试点结果显示仍有优化空间。
PLoS One. 2014 Nov 11;9(11):e112159. doi: 10.1371/journal.pone.0112159. eCollection 2014.
8
Comprehensive molecular profiling of lung adenocarcinoma.肺腺癌的全面分子分析。
Nature. 2014 Jul 31;511(7511):543-50. doi: 10.1038/nature13385. Epub 2014 Jul 9.
9
ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.ALK、ROS1 和 RET 融合在 1139 例肺腺癌中的综合研究:常见和融合模式特异性临床病理、组织学和细胞学特征。
Lung Cancer. 2014 May;84(2):121-6. doi: 10.1016/j.lungcan.2014.02.007. Epub 2014 Feb 19.
10
A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer.一种用于检测肺癌中ALK、ROS1和RET融合的单管多重检测法。
J Mol Diagn. 2014 Mar;16(2):229-43. doi: 10.1016/j.jmoldx.2013.11.007. Epub 2014 Jan 10.